Acute Leukemia
Conditions
Brief summary
LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy. Specifically: 1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells. 2. The association between immunometabolic signatures and response to therapies will be assessed. 3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.
Detailed description
Multicentre biological study, aimed at collecting and characterising human tissue isolated from acute leukaemia patients. In the context of routine care visits, peripheral blood (PB) and bone marrow (BM) samples will be taken from these patients at different time-points, which will be compared with samples obtained from healthy control subjects.Patients belonging to the haematology OU of the IRCCS AOU of Bologna and to the haematology OUs of the participating centres, suffering from acute leukaemia, will be enrolled. They must be eligible for a treatment scheme that includes either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies, as part of the normal care pathway. It is also planned to enrol healthy donors whose samples will be provided by: * IRCCS AOU of Bologna Immunohaematology and Transfusion Medicine Service (buffy coat) * Italian Association against Leukaemia, Lymphoma and Myeloma in Bologna (AIL BOLOGNA ODV), within the Haematology Unit of the IRCCS AOU of Bologna (peripheral blood).
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
PATIENT * Diagnosis of Acute Leukaemia. * Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies. * age ≥ 18 years. * Signature of informed consent by patients at the time of diagnosis. Healthy donors (AIL BOLOGNA ODV volunteers) * age ≥ 18 years. * Signature of informed consent.
Exclusion criteria
* no one
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system, in order to identify immuno-modulatory metabolic mechanisms implemented by malignant cells | Once the sample is collected, through study completion, an average of 1 year | molecular and metabolic characterisation of the bone marrow infiltrate |
| the association between immunometabolic signatures and response to therapies | Once the sample is collected, through study completion, an average of 1 year | evaluation of the immunometabolic profile pre- and post therapy and possible relapse |
| the role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells | Once the sample is collected, through study completion, an average of 1 year | Characterisation of the vesicular component EV and by modulating various metabolic |
Countries
Italy
Contacts
Primary ContactAntonio Curti, MD
Outcome results
None listed